Login to Your Account

Series B relates $83.5M for vectors to Homology, near clinical

By Randy Osborne
Staff Writer

Tuesday, August 1, 2017

Homology Medicines Inc. CEO Arthur Tzianabos told BioWorld that the new $83.5 million in series B money should let the firm "move our lead program all the way through a phase I/II proof-of-concept trial" while edging toward the clinic.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription